Swiss Pharma Company – IDEOGEN takes over Special Access Program for BELEODAQ® (belinostat)
IDEOGEN GROUP, Managed Access division, takes over Special Access Program for BELEODAQ® (belinostat) in Europe, Middle East, North Africa, Russia, and CIS. BELEODAQ® is a prescription medicine used to treat patients with a rare form of blood cancer called peripheral T-cell lymphoma (PTCL) that relapsed or does not respond to previous treatment. PTCL is a group of rare […]
